David OMalley, Professor and Division Director of Gynecologic Oncology, Co-Director, The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, shared a post on LinkedIn:
“Proud to share the publication of PRO-PLATINUM in Gynecologic Oncology!
This randomized, double-blind, placebo-controlled trial is what bench to bedside looks like in practice. Collaborative microbiome science from the Chambers and Spakowicz labs at The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute has now been translated into a prospective, interventional clinical trial testing whether a rationally selected probiotic formulation can favorably modulate the microbiome during platinum chemotherapy and improve outcomes for our patients.
This is exactly the kind of investigator-driven science that moves the field forward.
Congratulations to Dr. Laura Chambers, Dr. Dan Spakowicz, and the entire team!”
Title: PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy
Authors: Laura M. Chambers, Daniel Spakowicz, Julia Chalif, Reed O’Connor, Quinn Kistenfeger, Yogita Mehra, Mohamed Mohssen, Cassidy Abdeen, Paulina Haight, Christa Nagel, Robert Neff, David Cohn, Larry J. Copeland, Floor Backes, Casey Cosgrove, John Hays, Caroline Dravillas, Eric McLaughlin, David O’Malley
Other articles featuring David OMalley on OncoDaily.